Small nuclear ribonucleoproteins: Difference between revisions
imported>Howard C. Berkowitz (New page: {{subpages}} <!-- Text is transcluded from the BASEPAGENAME/Definition subpage-->) |
mNo edit summary |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Small nuclear ribonucleoproteins''' are highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus<ref>{{MeSH}}</ref> Antibodies to these proteins may be clinically significant in a number of [[rheumatology|rheumatological diseases]]. | |||
"[[Systemic lupus erythematosus]] is characterized by production of autoantibodies to RNA or DNA–protein complexes such as small nuclear ribonucleoproteins (snRNPs). A role of Epstein–Barr virus in the pathogenesis has been suggested. Similar to Epstein–Barr virus, cytomegalovirus (CMV) infects the majority of individuals at a young age and establishes latency with a potential for reactivation...CMV [may have a role] in regulation of autoantibodies to snRNPs" <ref>{{citation | |||
| title=Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies | |||
| author = Claudia Azucena Palafox Sánchez ''et al.'' | |||
| journal = Arthritis Research & Therapy | |||
| year = 2009 | volume = 11 | page = R27 | doi=10.1186/ar2621 | |||
| url = http://arthritis-research.com/content/11/1/R27}}</ref> | |||
Antibodies against the subclass [[U1 small nuclear ribonucleoprotein]]s (anti-U1 snRNP OR anti-U1 RNP) are characteristic of [[mixed connective tissue disease]].<ref>{{citation | |||
| journal = eMedicine Specialties > Rheumatology > Systemic Rheumatic Disease | |||
| title =Mixed Connective-Tissue Disease: Overview | |||
| author =Robert W Hoffman and Eric L Greidinger | |||
| date = 7 August 2008 | |||
| url = http://emedicine.medscape.com/article/335815-overview}}</ref> | |||
==References== | |||
{{reflist|2}}[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 06:01, 19 October 2024
Small nuclear ribonucleoproteins are highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus[1] Antibodies to these proteins may be clinically significant in a number of rheumatological diseases.
"Systemic lupus erythematosus is characterized by production of autoantibodies to RNA or DNA–protein complexes such as small nuclear ribonucleoproteins (snRNPs). A role of Epstein–Barr virus in the pathogenesis has been suggested. Similar to Epstein–Barr virus, cytomegalovirus (CMV) infects the majority of individuals at a young age and establishes latency with a potential for reactivation...CMV [may have a role] in regulation of autoantibodies to snRNPs" [2]
Antibodies against the subclass U1 small nuclear ribonucleoproteins (anti-U1 snRNP OR anti-U1 RNP) are characteristic of mixed connective tissue disease.[3]
References
- ↑ Anonymous (2024), Small nuclear ribonucleoproteins (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Claudia Azucena Palafox Sánchez et al. (2009), "Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies", Arthritis Research & Therapy 11: R27, DOI:10.1186/ar2621
- ↑ Robert W Hoffman and Eric L Greidinger (7 August 2008), "Mixed Connective-Tissue Disease: Overview", eMedicine Specialties > Rheumatology > Systemic Rheumatic Disease